These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 12547154

  • 21. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
    Sacha T, Hochhaus A, Hanfstein B, Müller MC, Rudzki Z, Czopek J, Wolska-Smoleń T, Czekalska S, Salamanchuk Z, Jakóbczyk M, Skotnicki AB.
    Leuk Res; 2003 Dec; 27(12):1163-6. PubMed ID: 12921956
    [Abstract] [Full Text] [Related]

  • 22. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [Abstract] [Full Text] [Related]

  • 23. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
    Thiele J, Kvasnicka HM, Varus E, Ollig E, Schmitt-Graeff A, Staib P, Griesshammer M.
    Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
    [Abstract] [Full Text] [Related]

  • 24. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Lu DP.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec 18; 37(6):612-5. PubMed ID: 16378113
    [Abstract] [Full Text] [Related]

  • 25. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K.
    Stem Cells Dev; 2007 Jun 18; 16(3):503-14. PubMed ID: 17610380
    [Abstract] [Full Text] [Related]

  • 26. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.
    Mol Cancer Ther; 2009 Sep 18; 8(9):2509-16. PubMed ID: 19723894
    [Abstract] [Full Text] [Related]

  • 27. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
    Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL.
    Cancer Cell; 2002 Aug 18; 2(2):117-25. PubMed ID: 12204532
    [Abstract] [Full Text] [Related]

  • 28. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 Aug 18; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 Aug 18; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 31. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
    Moravcová J, Zmeková V, Klamová H, Voglová J, Faber E, Michalová K, Rabasová J, Jarosová M.
    Leuk Res; 2004 Apr 18; 28(4):415-9. PubMed ID: 15109543
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS.
    Exp Hematol; 2010 Sep 18; 38(9):773-81. PubMed ID: 20438801
    [Abstract] [Full Text] [Related]

  • 34. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.
    Blood; 2002 Jul 15; 100(2):435-41. PubMed ID: 12091333
    [Abstract] [Full Text] [Related]

  • 35. Pathobiology of lymphoid and myeloid blast crisis and management issues.
    Ilaria RL.
    Hematology Am Soc Hematol Educ Program; 2005 Jul 15; ():188-94. PubMed ID: 16304379
    [Abstract] [Full Text] [Related]

  • 36. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K, Warzocha K, Hellmann A, Skotnicki A, Prejzner W, Foryciarz K, Sacha T, Gniot M, Majewski M, Solarska I, Nowak G, Wasag B, Kobelski M, Scibiorski C, Siemiatkowski M, Lewandowska M, Komarnicki M.
    Pol Arch Med Wewn; 2009 Dec 15; 119(12):789-94. PubMed ID: 20010464
    [Abstract] [Full Text] [Related]

  • 37. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep 15; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 38. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
    Lee JJ, Kim HJ, Kim YJ, Lee S, Hwang JY, Kim YL, Kim DW.
    Leukemia; 2004 Sep 15; 18(9):1539-40. PubMed ID: 15284852
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P.
    Haematologica; 2010 Apr 15; 95(4):582-8. PubMed ID: 20015884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.